Dinaciclib
A cyclin-dependent kinase inhibitor used in cancer treatment
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = 2-[[3-[[2-[(aminocarbonyl)amino]ethyl]amino]-1H-indol-7-yl]oxy]-N-(5-quinolinylmethyl)benzamide
| image = Dinaciclib.svg
| width = 200px
}}
Dinaciclib is a small molecule inhibitor of cyclin-dependent kinases (CDKs), which are enzymes that play a crucial role in the regulation of the cell cycle. It is primarily investigated for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit | edit source]
Dinaciclib functions by inhibiting the activity of CDKs, particularly CDK1, CDK2, CDK5, and CDK9. These kinases are essential for the progression of the cell cycle and the transcription of genes necessary for cell proliferation. By inhibiting these kinases, dinaciclib can induce cell cycle arrest and promote apoptosis in cancer cells.
Clinical Development[edit | edit source]
Dinaciclib has been evaluated in several clinical trials for its efficacy and safety in treating different cancers, including leukemia, breast cancer, and lung cancer. The drug has shown promise in preclinical studies and early-phase clinical trials, demonstrating the ability to reduce tumor growth and enhance the effects of other anticancer agents.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of dinaciclib involves its absorption, distribution, metabolism, and excretion. It is administered intravenously, and its distribution in the body is characterized by a rapid clearance and a relatively short half-life. The metabolism of dinaciclib is primarily hepatic, and it is excreted through both renal and fecal pathways.
Side Effects[edit | edit source]
Common side effects associated with dinaciclib include neutropenia, thrombocytopenia, anemia, and gastrointestinal symptoms such as nausea and vomiting. These side effects are consistent with the drug's mechanism of action, as it affects rapidly dividing cells, including those in the bone marrow and gastrointestinal tract.
Research and Future Directions[edit | edit source]
Ongoing research is focused on optimizing the use of dinaciclib in combination with other therapeutic agents to enhance its anticancer efficacy. Studies are also exploring its potential role in overcoming resistance to other treatments and its application in a broader range of cancer types.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD